- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04832438
9-ING-41 Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma
Phase 2 Study of 9-ING-41, a Glycogen Synthase Kinase 3 Beta (GSK 3β) Inhibitor, Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
9-ING-41 is a small molecule potent selective GSK-3β inhibitor with antitumor activity. It acts through downregulation of NF-κB and decreases the expression NF-κB target genes cyclin D1, Bcl-2, anti-apoptotic protein (XIAP) and B-cell lymphoma-extra large (Bcl-XL) leading to inhibition of tumor growth in multiple solid tumor cell and lymphoma lines and patient derived xenograft (PDX) models. 9-ING-41 may also function as an immune modulatory agent by decreasing checkpoint expression and enhancement of T-cell / NK-cell effector function. This is a phase 2, open-label, non-randomized, single institution study investigating the novel glycogen synthase kinase-3 beta (GSK-3β) inhibitor 9-ING-41 in combination with carboplatin chemotherapy in patients with incurable, recurrent or metastatic salivary gland carcinomas (SGC). The safety of this combination has been established in the Actuate 1801 study. Thirty-one evaluable patients with advanced SGC (including all histologic subtypes and adenoid cystic carcinoma [ACC]) will receive 9-ING-41 intravenously (IV) along with carboplatin IV at standard dosing together on Day 1, and 9-ING-41 alone on Day 4 of a 21-day cycle. Participants will be enrolled to two histologic cohorts: Cohort 1 will be comprised of those with ACC, and Cohort 2 will include patients with non-ACC SGC (or all other salivary gland cancer histologies). Treatment will continue until progression of disease, death, or discontinuation of therapy for any reason.
The primary aim of the study is to assess the overall response rate (ORR) as defined by RECIST v1.1 in the overall study population (including both Cohorts 1 and 2). Secondary aims include assessing progression-free survival (PFS), overall survival (OS), determining safety and tolerability, measuring patient-reported quality of life metrics, and correlating efficacy with molecular and immunologic predictors of response. We hypothesize that the novel combination of a GSK-3β inhibitor with carboplatin chemotherapy will result in an ORR of 25% or greater in this patient population where no approved therapies have been established.
Study Type
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- Dana-Farber Cancer Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Participants must have histologically confirmed salivary gland carcinoma (any histologic subtype, including ACC) with evidence of recurrent, metastatic or advanced, unresectable disease.
- Willing to provide tumor tissue from a diagnostic biopsy or prior surgery.
- Age 18 years or older
- ECOG performance status 0-2 (see Appendix A)
Participant must have organ and marrow function as defined below within 14 days prior to study registration:
- leukocytes ≥ 3,000/mcL
- absolute neutrophil count ≥ 500/mcL
- hemoglobin ≥ 8.5 g/dL
- platelets ≥ 75,000/mcL
- total bilirubin ≤ 2.0 g/dL
- AST(SGOT)/ALT(SGPT) ≤ 2.5× institutional upper limit of normal
- creatinine within normal institutional limits OR
- creatinine clearance ≥50 mL/min/1.73 m2 for participants with creatinine levels above institutional normal
- Participants must have documentation of a new or progressive lesion on a radiologic imaging study performed within 12 months prior to study registration (progression of disease over any interval is allowed) and/or new or worsening disease-related symptoms within 12 months prior to study registration.
- Participants must have at least one RECIST v1.1 measurable non-CNS based lesion.
- Prior systemic therapy: At least 2 weeks must have elapsed since the end of prior chemotherapy, biological agents (3 weeks for anti-cancer monoclonal antibody containing regimens) or any investigational drug product, with adequate recovery of treatment-related toxicity to NCI CTCAE Version 5.0 grade ≤1 (or tolerable grade 2) or back to baseline (except for alopecia or neuropathy). Any number of prior therapies for recurrent/metastatic SGC are permitted (including prior carboplatin exposure).
- Ability to understand and the willingness to sign a written informed consent document.
- Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 72 hours prior to the start of study treatment.
- Men who are sexually active with WOCBP must agree to use any contraceptive method with a failure rate of less than 1% per year. Men who are sexually active with WOCBP will be instructed to adhere to contraception for a period of 90 days after the last dose of investigational product.
Exclusion Criteria:
- Metastatic disease impinging on the spinal cord or threatening spinal cord compression. Patients that have had previous treatment of disease with impinging on the cord with either surgery or radiotherapy with clinical or radiographic evidence of response or stability are eligible.
- Participant has known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Subjects with previously treated brain metastases may participate provided they are stable (without evidence of progression by imaging for at least four weeks prior to the first dose of trial treatment), and have no evidence of new or enlarging brain metastases.
- Concurrent administration of other cancer specific therapy or investigational agents during the course of this study is not allowed.
- Uncontrolled intercurrent illness including but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia.
- Pregnant or lactating women.
- Has a known additional malignancy that is progressing or requires active treatment. Exceptions include: basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer, and low-risk prostate adenocarcinoma being managed with active surveillance. A history of another separate malignancy in remission without evidence of active disease in the last 2 years is permitted.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: 9-ING-41 plus carboplatin
Patients will receive 9-ING-41 (15 mg/kg IV on Day 1 and Day 4) in addition to carboplatin (AUC 5 IV on Day 1) each of a 21-day cycle
|
15 mg/kg as intravenous infusion on Days 1 and Day 4 of a 21-day cycle
Carboplatin AUC 5 intravenously on Day 1 of a 21-day cycle
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of evaluable patients with objective response as measured by RECIST version 1.1
Time Frame: 3-24 months
|
Response and progression will be evaluated in this study using the international Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1).
Changes in the largest diameter (unidimensional measurement) of the tumor lesions and the shortest diameter in the case of malignant lymph nodes are used in the RECIST criteria.
|
3-24 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (ANTICIPATED)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Adenocarcinoma
- Neoplasms, Glandular and Epithelial
- Head and Neck Neoplasms
- Stomatognathic Diseases
- Mouth Diseases
- Salivary Gland Diseases
- Mouth Neoplasms
- Carcinoma
- Carcinoma, Adenoid Cystic
- Salivary Gland Neoplasms
- Antineoplastic Agents
- Carboplatin
Other Study ID Numbers
- 2102
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Adenoid Cystic Carcinoma
-
Glenn J. HannaAdenoid Cystic Carcinoma Research Foundation; Cellestia Biotech AGRecruitingAdenoid Cystic Carcinoma | Metastatic Adenoid Cystic Carcinoma | Recurrent Adenoid Cystic CarcinomaUnited States
-
M.D. Anderson Cancer CenterRecruitingAdenoid Cystic Carcinoma | Metastatic Adenoid Cystic CarcinomaUnited States
-
Dana-Farber Cancer InstituteAdenoid Cystic Carcinoma Research Foundation; Gateway for Cancer ResearchRecruitingAdenoid Cystic Carcinoma | Metastatic Adenoid Cystic CarcinomaUnited States
-
Dana-Farber Cancer InstituteAdenoid Cystic Carcinoma Research FoundationNot yet recruitingAdenoid Cystic Carcinoma | Adenoid Cystic Carcinoma of the Salivary GlandUnited States
-
Peking Union Medical College HospitalRecruitingMetastatic Adenoid Cystic Carcinoma | 68Ga-FAPI PET/CTChina
-
Remix TherapeuticsRecruitingAdenoid Cystic Carcinoma | Metastatic Adenoid Cystic Carcinoma | Recurrent Adenoid Cystic CarcinomaUnited States
-
Fudan UniversityCompletedCisplatin | Adenoid Cystic CarcinomasChina
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedMetastatic Adenoid Cystic Carcinoma | Progressive Disease | Recurrent Adenoid Cystic CarcinomaUnited States
-
Shanghai Ninth People's Hospital Affiliated to...RecruitingAdenoid Cystic Carcinoma of the Head and NeckChina
-
Ayala Pharmaceuticals, Inc,Memorial Sloan Kettering Cancer Center; Hadassah Medical Organization; Adenoid... and other collaboratorsCompleted
Clinical Trials on 9-ING-41
-
Actuate Therapeutics Inc.Completed
-
Glenn J. HannaActuate Therapeutics Inc.Active, not recruitingAdenoid Cystic Carcinoma | Metastatic Cancer | Salivary Gland Cancer | Recurrent Salivary Gland CancerUnited States
-
Anwaar SaeedActuate Therapeutics Inc.; Incyte CorporationActive, not recruitingPancreatic AdenocarcinomaUnited States
-
Actuate Therapeutics Inc.Active, not recruitingNeuroblastoma | Pediatric Cancer | Diffuse Intrinsic Pontine Glioma | Pediatric Brain Tumor | Refractory Cancer | Refractory Neoplasm | Refractory Tumor | Cancer Pediatric | Neuroblastoma Recurrent | Pediatric Lymphoma | Pediatric MeningiomaUnited States
-
Colin D. Weekes, M.D., PhDActuate Therapeutics Inc.; Lustgarten FoundationRecruitingPancreatic Adenocarcinoma | Pancreatic Adenocarcinoma MetastaticUnited States
-
Brown UniversityActuate Therapeutics Inc.WithdrawnSoft Tissue Sarcoma | Osteosarcoma | Ewing Sarcoma of Bone | Leiomyosarcoma | High Grade Sarcoma | Liposarcoma | Rhabdomyosarcoma | Angiosarcoma | Bone Sarcoma | Synovial Sarcoma | Undifferentiated Pleomorphic Sarcoma | Myxofibrosarcoma | Spindle Cell SarcomaUnited States
-
Brown UniversityActuate Therapeutics Inc.WithdrawnSarcoma | Soft Tissue Sarcoma | Leiomyosarcoma | High Grade Sarcoma | Liposarcoma | Rhabdomyosarcoma | Angiosarcoma | Bone Sarcoma | Synovial Sarcoma | Undifferentiated Pleomorphic Sarcoma | Metastatic Sarcoma | Myxofibrosarcoma | Spindle Cell SarcomaUnited States
-
Gannex Pharma Co., Ltd.Hunan Provincial People's HospitalCompletedNAFLD | Overweight and Obesity | HyperlipidemiaChina
-
XenoTherapeutics, Inc.Joseph M. Still Research Foundation, Inc.Active, not recruitingWound Heal | Thermal Burn | Burn Degree Second | Burns Degree Third | Burn (Disorder)United States
-
XOMA (US) LLCCompletedAdenocarcinomaUnited States